Pros | - | - | ||
Cons | - | - |
INDMoney rank | - | - | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 21 Years | ||
Fund Size | 2961 Cr | 8352 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.94% | 1.8% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 40 | ||
Top 5 Holdings | Cipla Ltd (8.86%) Cohance Lifesciences Ltd (8.81%) Sun Pharmaceuticals Industries Ltd (8.7%) Ipca Laboratories Ltd (8.16%) Gland Pharma Ltd (4.94%) | Sun Pharmaceuticals Industries Ltd (12.57%) Divi's Laboratories Ltd (9.49%) Lupin Ltd (5.82%) Cipla Ltd (5.62%) Dr Reddy's Laboratories Ltd (5.49%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.46%) Financial Services (1.54%) | Health (100%) | ||
Equity % | 99.58% | 98.58% | ||
Debt % | - | - | ||
P/E | 39.12 | 36.85 | ||
P/B | 5.04 | 5.96 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.76% | 2.25% | ||
3-Month Return | 0.91% | 4.6% | ||
6-Month Return | -7.2% | -1.24% | ||
1-Year Return | 14.99% | 13.81% | ||
3-Year Return | 26.14% | 25.72% | ||
5-Year Return | 22.74% | 21.75% |
Sharpe | 1.04 | 1.07 | ||
Alpha | 1.14 | 0.76 | ||
Beta | 0.86 | 0.89 | ||
Standard Deviation | 15.13 | 14.96 | ||
Information Ratio | -0.21 | -0.27 |
Description | DSP Healthcare Fund Regular Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Kinjal Desai,Sailesh Raj Bhan |